Wall Street Zen Upgrades Boston Scientific Stock to Buy

The medical device company's shares get a boost from a new analyst rating.

Mar. 14, 2026 at 6:33am

Got story updates? Submit your updates here. ›

Wall Street Zen, an investment research firm, has upgraded Boston Scientific Corporation's (NYSE:BSX) stock rating from "hold" to "buy" in a report issued on Saturday. The upgrade comes as Boston Scientific faces a challenging market environment, with analysts lowering their price targets for the company's shares in recent months.

Why it matters

The analyst upgrade could provide a much-needed boost to Boston Scientific's stock price, which has declined significantly in recent weeks amid broader market volatility and concerns about the company's business outlook. The upgrade signals that at least one research firm sees value in Boston Scientific's long-term prospects, despite the near-term headwinds.

The details

In its report, Wall Street Zen cited Boston Scientific's strong product pipeline and its leadership position in several key medical device markets as reasons for the upgrade. The firm also noted that the company's recent cost-cutting initiatives and efforts to streamline its operations could help improve profitability in the coming quarters.

  • Wall Street Zen issued the upgrade report on Saturday, March 14, 2026.

The players

Wall Street Zen

An investment research firm that provides analysis and ratings on publicly traded companies.

Boston Scientific Corporation

A global medical device company that develops, manufactures, and markets a broad portfolio of products used in less-invasive medical procedures.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident

The takeaway

The Wall Street Zen upgrade provides a glimmer of hope for Boston Scientific investors, who have seen the company's stock price decline in recent months. However, the company still faces significant challenges, including increased competition and regulatory scrutiny, and investors will be closely watching the company's performance in the coming quarters to see if the upgrade is justified.